Table 1. Baseline characteristics.
| Total | SR | AF | P | P adjusted for age | |
| n = 439 | n = 326 (74.3%) | n = 113 (25.7%) | |||
| Female | 239 ± 54.4 | 189 ± 79.1 | 50 ± 20.1 | 0.012 | |
| Age, yrs | 78.4 (6.7%) | 77.6 (6.8%) | 80.5 (6.0%) | < 0.001 | |
| Died within study period | 10 (2.3%) | 7 (2.1%) | 3 (2.7%) | 0.755 | |
| Number of morbidities | 5 ± 2.6 | 5 ± 2.3 | 7 ± 2.7 | < 0.001 | < 0.001 |
| Number of drugs | 6 ± 3.9 | 6 ± 3.9 | 7 ± 3.6 | 0.001 | 0.017 |
| Polypharmacy (≥ 5 drugs) | 254 (57.9%) | 168 (51.5%) | 86 (76.1%) | < 0.001 | < 0.001 |
| Hypertension | 278 (63.3%) | 194 (59.5%) | 84 (74.3%) | 0.005 | 0.018 |
| Hypercholesterolemia | 187 (42.6%) | 133 (40.8%) | 54 (47.8%) | 0.195 | |
| Diabetes mellitus | 98 (22.3%) | 69 (21.2%) | 29 (25.7%) | 0.322 | |
| CHA2DS2VASc | 3.8 ± 1.5 | 3.6 ± 1.4 | 4.3 ± 1.4 | < 0.001 | < 0.001 |
| HAS-BLED | 1.5 ± 0.7 | 1.5 ± 0.7 | 1.6 ± 1.4 | 0.195 | |
| All strokes, (stroke and/or TIA) | 68 (15.5%) | 42 (12.9%) | 26 (23.0%) | 0.010 | 0.015 |
| Heart failure | 49 (11.2%) | 19 (5.8%) | 30 (26.5%) | < 0.001 | < 0.001 |
| *Ischemic heart disease | 95 (21.6%) | 62 (19.0%) | 33 (29.2%) | 0.023 | 0.025 |
| Peripheral artery disease | 38 (8.7%) | 24 (7.4%) | 14 (12.4%) | 0.101 | |
| Hypothyroidism | 31 (7.1%) | 17 (5.2%) | 14 (12.4%) | 0.010 | 0.047 |
| Hyperthyroidism | 12 (2.7%) | 3 (0.9%) | 9 (8.0%) | < 0.001 | < 0.001 |
| COPD | 65 (14.8%) | 49 (15.0%) | 16 (14.2%) | 0.822 | |
| Chronic kidney disease, ≥ stage 3 | 60 (13.7%) | 35 (10.7%) | 25 (22.1%) | 0.002 | 0.011 |
| Syncope | 74 (16.9%) | 46 (14.1%) | 28 (24.8%) | 0.009 | 0.009 |
| Orthostatic hypotension | 95 (21.6%) | 57 (17.5%) | 38 (33.6%) | < 0.001 | 0.002 |
Data are presented as n (%) or mean ± SD. *Angina pectoris, myocardial infarction, cardiac artery bypass or percutaneous coronary intervention. AF: atrial fibrillation; BMI: body mass index; COPD: chronic obstructive lung disease; SR: sinus rhythm; TIA: transient ischemic attack.